Table 1.

Determinants of increased plasma Hcy concentrations in liver transplant patients.1

Increased tHcy (%)2Odds ratio (95% CI)
Men (n = 141)/Women (n = 80)75 (53)/28 (35)2.11 (1.16–3.88)3
Age ≥55 years (n = 136)/Age <55 years (n = 85)72 (85)/31 (23)1.96 (1.09–3.56)3
Months since transplant ≥60 (n = 98)/<60 (n = 123)49 (50)/54 (31)1.28 (0.72–2.25)
Cyclosporine (n = 119)/Tacrolimus therapy (n = 102)69 (58)/34 (33)2.76 (1.54–4.97)4
Obesity (n = 48)/Nonobesity (n = 173)21 (46)/82 (47)0.95 (0.47–1.93)
Smokers (n = 66)/Nonsmokers (n = 155)35 (53)/68 (44)1.59 (0.85–2.99)
Diabetes (n = 55)/No diabetes (n = 166)28 (51)/79 (48)1.14 (0.59–2.20)
Hypertensive (n = 97)/Normotensive (n = 124)54 (56)/49 (39)1.92 (1.08–3.42)3
Hypercholesterolemic (n = 80)/Nonhypercholesterolemic (n = 141)37 (46)/66 (47)0.98 (0.54–1.77)
  • 1 χ2 test was used for statistical analysis. Smoker was defined as any cigarette smoking in the past month. Obesity was defined as BMI ≥30 kg/m2. Hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg more than two times during the preceding year or the need for antihypertensive treatment. Hypercholesterolemia was defined as a fasting LDL-cholesterol concentration ≥3.4 mmol/L or the need for antilipemic agents. Diabetes was defined as a fasting plasma glucose ≥7.0 mmol/L on two different days during the year preceding the study or the need for antidiabetic agents.

  • 2 Homocysteine values greater than means +2 SD of control values (≥14.5 μmol/L).

  • 3 P <0.05.

  • 4 P <0.001.